XENON PHARMACEUTICALS INC (XENE)
CA98420N1050 - Common Stock
| 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 148.64M | 57.20M | 175.70M | 45.00M | 24.80M | |||
| Marketable Securities | 489.44M | 534.80M | 376.10M | 132.00M | 116.60M | |||
| Receivables | 874.00K | 1.00M | 2.80M | 1.80M | 800.00K | |||
| Other Current Assets | 6.01M | 7.20M | 4.50M | 3.00M | 2.70M | |||
| Total Current Assets | 644.96M | 600.30M | 559.00M | 181.80M | 144.90M | |||
| Non-Current Assets | ||||||||
| PPE Net | 18.85M | 16.90M | 12.50M | 6.90M | 2.60M | |||
| Investments And Advances | 292.79M | 128.70M | N/A | N/A | N/A | |||
| Other Non-Current Assets | 8.20M | 8.30M | 500.00K | 500.00K | 200.00K | |||
| Total Non-Current Assets | 319.84M | 153.80M | 13.00M | 7.40M | 2.80M | |||
| TOTAL ASSETS | 964.80M | 754.10M | 572.00M | 189.20M | 147.70M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | N/A | N/A | N/A | N/A | 4.70M | |||
| Accrued Expenses | 18.33M | 13.90M | 10.40M | 8.00M | 6.30M | |||
| Accounts Payable | 8.95M | 8.80M | 3.90M | 3.10M | 2.70M | |||
| Other Current Liabilities | N/A | N/A | 0.00 | 3.60M | 29.70M | |||
| Total Current Liabilities | 27.27M | 22.70M | 14.30M | 14.80M | 43.40M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 10.90M | |||
| Other Non-Current Liabilities | 9.60M | 9.90M | 7.70M | 3.10M | 1.50M | |||
| Total Non-Current Liabilities | 9.60M | 9.90M | 7.70M | 3.00M | 12.30M | |||
| TOTAL LIABILITIES | 36.88M | 32.60M | 22.00M | 17.80M | 55.70M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -665.14M | -482.70M | -357.40M | -278.50M | -249.70M | |||
| Additional Paid In Capital | 156.76M | 142.10M | 117.50M | 45.40M | 40.60M | |||
| Common Shares | 1.44B | 1.07B | 790.90M | 405.40M | 301.90M | |||
| Other Shareholders' Equity | -77.00K | -3.00M | -1.00M | -1.00M | -1.00M | |||
| Shares Outstanding | 75.37M | 62.60M | 51.60M | 35.00M | 28.10M | |||
| Tangible Book Value per Share | 12.31 | 11.53 | 10.51 | 4.68 | 3.00 | |||
| Total Shareholders' Equity | 927.92M | 721.50M | 550.00M | 171.40M | 92.00M | |||
| TOTAL LIABILITIES AND EQUITY | 964.80M | 754.10M | 572.00M | 189.20M | 147.70M | |||
| Statistics | ||||||||
| Debt/Equity | N/A | N/A | N/A | N/A | 0.12 | |||
| Current Ratio | 23.65 | 26.44 | 39.09 | 12.28 | 3.34 | |||
| Return On Assets (ROA) | -18.90% | -16.57% | -13.48% | -14.80% | -27.10% | |||
| Return On Equity (ROE) | -19.66% | -17.32% | -14.02% | -16.34% | -43.51% | |||
| Return On Invested Capital (ROIC) | N/A | N/A | N/A | N/A | N/A | |||
All data in USD